According to GuruFocus Insider Data, the largest CFO buys during the past week were Inuvo Inc., Heelys Inc., Peregrine Pharmaceuticals Inc., Anthera Pharmaceuticals Inc., and FedFirst Financial Corp.
Inuvo Inc. (INUV, Financial): CFO Wallace D Ruiz Bought 10,130 Shares
CFO of Inuvo Inc. (INUV) Wallace D Ruiz bought 10,130 shares on 09/15/2010 at an average price of $0.29. Kowabunga!, Inc. enables online media buyers to generate conversions more efficiently across a wide range of online media. Inuvo Inc. has a market cap of $24.7 million; its shares were traded at around $0.2899 with and P/S ratio of 0.6.
Inuvo, Inc. announced its financial results for the second quarter ended June 30, 2010. Inuvo reported that revenue for the quarter ended June 30, 2010 was $11.5 million, a 20% increase over the first quarter of 2010 and a 21% increase from the same quarter last year. The net loss for the second quarter was $1.1 million compared to a net loss of $773 thousand for the same period last year. The increased loss was the result of discontinued operations, which reported a net loss of $7 thousand in the second quarter of 2010 versus $508 thousand of net income in the same quarter last year.
INUV is in the portfolios of Jim Simons of Renaissance Technologies LLC.
CEO Richard K Howe, CFO Wallace D Ruiz, and Director Charles D Morgan bought shares of INUV stock.
Heelys Inc. (HLYS, Financial): CFO/COO Craig D Storey Bought 8,500 Shares
CFO/COO of Heelys Inc. (HLYS) Craig D Storey bought 8,500 shares on 09/16/2010 at an average price of $2.48. HEELYS, INC. designs, markets and distributes innovative, action sports-inspired products under the HEELYS brand targeted to the youth market. Heelys Inc. has a market cap of $65.4 million; its shares were traded at around $2.37 with and P/S ratio of 1.5.
Heelys, Inc. reported the following financial results for the second quarter ended June 30, 2010. Net sales for the second quarter of 2010 were $8.8 million compared to net sales of $6.7 million in the first quarter of 2010. The Company reported net income of $473,000, or $0.02 per fully diluted share, versus a net loss of $1.6 million, or ($0.06) per fully diluted share in the second quarter of 2009.
HLYS is in the portfolios of Jim Simons of Renaissance Technologies LLC and Mario Gabelli of GAMCO Investors.
CFO/COO Craig D Storey bought shares of HLYS stock.
10% Owner Roger Ralph Adams sold shares of HLYS stock.
Peregrine Pharmaceuticals Inc. (PPHM, Financial): CFO Paul J Lytle Bought 5,000 Shares
CFO of Peregrine Pharmaceuticals Inc. (PPHM) Paul J Lytle bought 5,000 shares on 09/23/2010 at an average price of $1.33. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. Peregrine Pharmaceuticals Inc. has a market cap of $75.4 million; its shares were traded at around $1.37 with and P/S ratio of 2.7.
Peregrine Pharmaceuticals, Inc. announced its clinical progress and financial results for the first quarter ended July 31, 2010 for its fiscal year (FY) 2011. Peregrine's consolidated net loss was $7,695,000, or $0.14 per share, for the first quarter of FY 2011, compared to a net loss of $2,428,000 or $0.05 per share, for the same quarter of the prior year. Total revenues for the first quarter of FY 2011 were $3,209,000, compared to $6,750,000 for the same quarter of the prior fiscal year.
PPHM is in the portfolios of Jim Simons of Renaissance Technologies LLC and Steven Cohen of SAC Capital Advisors.
President & CEO Steven W King and CFO Paul J Lytle bought shares of PPHM stock.
Anthera Pharmaceuticals Inc. (ANTH, Financial): CFO & VP of Administration Christopher P. Lowe Bought 5,000 Shares
CFO & VP of Administration of Anthera Pharmaceuticals Inc. (ANTH) Christopher P. Lowe bought 5,000 shares on 09/24/2010 at an average price of $4.18. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. Anthera Pharmaceuticals Inc. has a market cap of $93.8 million; its shares were traded at around $4.2 .
Anthera Pharmaceuticals, Inc. announced financial results and business highlights for the second quarter ended June 30, 2010. Total operating expenses for the second quarter ended June 30, 2010, were $7.9 million, as compared to $3.3 million for the same period in 2009. Anthera ended the second quarter of 2010 with approximately $51.0 million in cash and cash equivalents and short-term investments.
ANTH is in the portfolios of Columbia Wanger of Columbia Wanger Asset Management and Steven Cohen of SAC Capital Advisors.
CFO & VP of Administration Christopher P. Lowe, VP, Pharmaceutical R&D Debra Odink, Sr. VP, Cardiovasc. Prod. Colin Hislop and bought shares of ANTH stock
FedFirst Financial Corp. (FFCOD, Financial): EVP & CFO Robert R Barry Jr Bought 3,000 Shares
EVP & CFO of FedFirst Financial Corp. (FFCOD) Robert R Barry Jr bought 3,000 shares on 09/21/2010 at an average price of $10. .
FFCOD is in the portfolios of Martin Whitman of Third Avenue Value Fund and Third Avenue Management.
President & CEO Patrick G Obrien, EVP & CFO Robert R Barry Jr, and Director David L Wohleber bought shares of FFCOD stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
Inuvo Inc. (INUV, Financial): CFO Wallace D Ruiz Bought 10,130 Shares
CFO of Inuvo Inc. (INUV) Wallace D Ruiz bought 10,130 shares on 09/15/2010 at an average price of $0.29. Kowabunga!, Inc. enables online media buyers to generate conversions more efficiently across a wide range of online media. Inuvo Inc. has a market cap of $24.7 million; its shares were traded at around $0.2899 with and P/S ratio of 0.6.
Inuvo, Inc. announced its financial results for the second quarter ended June 30, 2010. Inuvo reported that revenue for the quarter ended June 30, 2010 was $11.5 million, a 20% increase over the first quarter of 2010 and a 21% increase from the same quarter last year. The net loss for the second quarter was $1.1 million compared to a net loss of $773 thousand for the same period last year. The increased loss was the result of discontinued operations, which reported a net loss of $7 thousand in the second quarter of 2010 versus $508 thousand of net income in the same quarter last year.
INUV is in the portfolios of Jim Simons of Renaissance Technologies LLC.
CEO Richard K Howe, CFO Wallace D Ruiz, and Director Charles D Morgan bought shares of INUV stock.
Heelys Inc. (HLYS, Financial): CFO/COO Craig D Storey Bought 8,500 Shares
CFO/COO of Heelys Inc. (HLYS) Craig D Storey bought 8,500 shares on 09/16/2010 at an average price of $2.48. HEELYS, INC. designs, markets and distributes innovative, action sports-inspired products under the HEELYS brand targeted to the youth market. Heelys Inc. has a market cap of $65.4 million; its shares were traded at around $2.37 with and P/S ratio of 1.5.
Heelys, Inc. reported the following financial results for the second quarter ended June 30, 2010. Net sales for the second quarter of 2010 were $8.8 million compared to net sales of $6.7 million in the first quarter of 2010. The Company reported net income of $473,000, or $0.02 per fully diluted share, versus a net loss of $1.6 million, or ($0.06) per fully diluted share in the second quarter of 2009.
HLYS is in the portfolios of Jim Simons of Renaissance Technologies LLC and Mario Gabelli of GAMCO Investors.
CFO/COO Craig D Storey bought shares of HLYS stock.
10% Owner Roger Ralph Adams sold shares of HLYS stock.
Peregrine Pharmaceuticals Inc. (PPHM, Financial): CFO Paul J Lytle Bought 5,000 Shares
CFO of Peregrine Pharmaceuticals Inc. (PPHM) Paul J Lytle bought 5,000 shares on 09/23/2010 at an average price of $1.33. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. Peregrine Pharmaceuticals Inc. has a market cap of $75.4 million; its shares were traded at around $1.37 with and P/S ratio of 2.7.
Peregrine Pharmaceuticals, Inc. announced its clinical progress and financial results for the first quarter ended July 31, 2010 for its fiscal year (FY) 2011. Peregrine's consolidated net loss was $7,695,000, or $0.14 per share, for the first quarter of FY 2011, compared to a net loss of $2,428,000 or $0.05 per share, for the same quarter of the prior year. Total revenues for the first quarter of FY 2011 were $3,209,000, compared to $6,750,000 for the same quarter of the prior fiscal year.
PPHM is in the portfolios of Jim Simons of Renaissance Technologies LLC and Steven Cohen of SAC Capital Advisors.
President & CEO Steven W King and CFO Paul J Lytle bought shares of PPHM stock.
Anthera Pharmaceuticals Inc. (ANTH, Financial): CFO & VP of Administration Christopher P. Lowe Bought 5,000 Shares
CFO & VP of Administration of Anthera Pharmaceuticals Inc. (ANTH) Christopher P. Lowe bought 5,000 shares on 09/24/2010 at an average price of $4.18. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. Anthera Pharmaceuticals Inc. has a market cap of $93.8 million; its shares were traded at around $4.2 .
Anthera Pharmaceuticals, Inc. announced financial results and business highlights for the second quarter ended June 30, 2010. Total operating expenses for the second quarter ended June 30, 2010, were $7.9 million, as compared to $3.3 million for the same period in 2009. Anthera ended the second quarter of 2010 with approximately $51.0 million in cash and cash equivalents and short-term investments.
ANTH is in the portfolios of Columbia Wanger of Columbia Wanger Asset Management and Steven Cohen of SAC Capital Advisors.
CFO & VP of Administration Christopher P. Lowe, VP, Pharmaceutical R&D Debra Odink, Sr. VP, Cardiovasc. Prod. Colin Hislop and bought shares of ANTH stock
FedFirst Financial Corp. (FFCOD, Financial): EVP & CFO Robert R Barry Jr Bought 3,000 Shares
EVP & CFO of FedFirst Financial Corp. (FFCOD) Robert R Barry Jr bought 3,000 shares on 09/21/2010 at an average price of $10. .
FFCOD is in the portfolios of Martin Whitman of Third Avenue Value Fund and Third Avenue Management.
President & CEO Patrick G Obrien, EVP & CFO Robert R Barry Jr, and Director David L Wohleber bought shares of FFCOD stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
